BioCentury

Since its inception in 1993, BioCentury, Inc. has earned a global reputation as a top source of valuable insights, analysis, and data for those in the biotechnology and pharmaceutical sectors, as well as investors, academic institutions, and government entities. They focus on key strategic issues that are vital for creating, growing, and maintaining life science companies. BioCentury utilizes a comprehensive multimedia approach that encompasses publications, videos, online data tools, and conferences. This allows them to offer their audience reliable and current information on various topics, including corporate strategies, partnerships, emerging technologies, clinical research, public policies, and financial markets. The editorial and research teams at BioCentury consist of well-respected editors and writers in both business and science. The company is led by a management team with diverse expertise, including international business, publishing, finance, and experience in the biotech and pharmaceutical fields. BioCentury is based in Redwood City, California, with additional offices located in Washington, D.C.; Chicago; and London.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#722082

United States

#316639

Health/Biotechnology and Pharmaceuticals

#303

Traffic sources

Monthly visitors

Articles

Can the U.S. turmoil make this Europe’s moment to shine? A Perspective

5 days ago | biocentury.com | Stephen Hansen

ARTICLE | BioCentury CommentaryWith U.S. institutions under strain, Europe must act decisively to support innovation and secure a bigger role in biotech’s future By Stephen Hansen, Director of Biopharma IntelligenceIn the 18 years I’ve been covering the biopharma industry, FDA and NIH have always been the unquestioned gold standard for regulating the sector and fueling the basic research necessary to advance new, innovative therapeutics.
Can the U.S. turmoil make this

6 days ago | biocentury.com | Stephen Hansen

ARTICLE | BioCentury CommentaryWith U.S. institutions under strain, Europe must act decisively to support innovation and secure a bigger role in biotech’s future By Stephen Hansen, Director of Biopharma IntelligenceIn the 18 years I’ve been covering the biopharma industry, FDA and NIH have always been the unquestioned gold standard for regulating the sector and fueling the basic research necessary to advance new, innovative therapeutics.
Earlybird, Sofinnova back Swiss start-up Haya in move toward clinic: Finance Report

6 days ago | biocentury.com | Paul Bonanos

ARTICLE | FinancePlus: Deerfield raises $600M for next vehicle, Vivo’s refreshed evergreen fund, and more By Paul Bonanos, Director of Biopharma IntelligenceSwitzerland-based Haya will move its lead long non-coding RNA program into this clinic with a new $65 million series A round, designed to deliver proof-of-concept data in patients with heart failure.
SMARCA2: The next big opportunity for degraders?

6 days ago | biocentury.com | Lauren Martz

ARTICLE | Product DevelopmentTargeted protein degraders and selective small molecules face off against SMARCA4-mutant cancers at AACR By Lauren Martz, Executive Director, Biopharma IntelligenceNow that targeted protein degraders have achieved clinical validation against established targets, companies are shifting focus to the modality’s primary value proposition: drugging the undruggable.
Zapata-Gomez succeeds Holstein as Biontech CFO, BMS’s Leung retiring as general counsel

6 days ago | biocentury.com | Paul Bonanos

ARTICLE | Management TracksPlus: Updates from Enara, Paq, Priothera, Eccogene By Paul Bonanos, Director of Biopharma Intelligence, and Jeff Cranmer, Executive Editor and Head of Daily Global intelligenceBiontech SE (NASDAQ:BNTX) named Ramón Zapata-Gomez CFO, succeeding the retiring Jens Holstein on July 1. Since 2022, Zapata-Gomez has been CFO of The Novartis Biomedical Research unit of Novartis AG (SIX:NOVN; NYSE:NVS).
Science Spotlight: Balancing safety and efficacy with dual TCR/CAR T cells

1 week ago | biocentury.com | Danielle Golovin

ARTICLE | Discovery & TranslationBioCentury’s roundup of translational innovations also includes microglia replacement for neurological disorders and enhanced mRNA vaccine efficacy By Danielle Golovin, Senior Biopharma Analyst A team of scientists, mostly from the National Cancer Institute, created dual TCR/CAR T cells that killed tumors with minimal toxicity to healthy tissue, a problem that has limited CAR T cell applicability to solid tumors.
Novo’s GLP-1s see another 1Q sales dip

1 week ago | biocentury.com | Stephen Hansen

DATA GRAPHICS | Data ByteCompounded GLP-1s impact 1Q25 sales growth By Stephen Hansen, Director of Biopharma IntelligenceFor the second year in a row, Novo’s semaglutide franchise got off to a slow start. In 1Q25, sales of the pharma’s three GLP-1R agonist formulations — Ozempic, Wegovy and Rybelsus — declined quarter-over-quarter, as reported in DKK. However, Ozempic sales were up slightly in U.S. dollars (see Chart).
Boehringer Venture’s high risk, high reward strategy enters next phase

1 week ago | biocentury.com | Stephen Hansen

ARTICLE | FinanceHow the corporate VC is evolving its portfolio strategy By Stephen Hansen, Director of Biopharma Intelligence Boehringer Ingelheim Venture Fundis sharpening its approach as it continues to seek investments that could be of strategic interest to the German pharma in the long term. The fund’s dual focus on breakthrough therapeutics in non-core areas and novel modalities within core areas had skewed toward the former. Now, new leadership aims to bring the two back into balance.
Insight into ovarian cancer treatment resistance: Literature Dive

1 week ago | biocentury.com | Danielle Golovin

ARTICLE | Discovery & TranslationFour tumor atlases point to target vulnerabilities and predictive signatures in epithelial ovarian cancers By Danielle Golovin, Senior Biopharma AnalystFour studies characterizing the molecular landscape of epithelial ovarian cancers describe molecular signatures that predict patient outcomes, and highlight potential mechanisms of resistance and response to chemotherapy and immunotherapy.
PTC hits Huntington biomarker, but approval path still uncertain

1 week ago | biocentury.com | Lauren Martz

ARTICLE | Product DevelopmentPlus: Stock-driving data from Alphamab; hits and misses in retinal gene therapy; Celiac proof of concept data; and more By Lauren Martz, Executive Director of Biopharma Intelligence, Paul Bonanos, Director of Biopharma Intelligence, and Selina Koch, Executive EditorDespite meeting the primary endpoint, new Phase II data from PTC failed to clarify the path to accelerated approval of PTC518 to treat Huntington disease, sending the company’s shares down 19% Monday.